Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amplia Therapeutics ( (AU:ATX) ) just unveiled an update.
Amplia Therapeutics has announced a new partial response in its ongoing ACCENT trial for advanced pancreatic cancer, increasing the response rate to 31% with its FAK inhibitor narmafotinib combined with standard chemotherapies. This result surpasses the 23% response rate of chemotherapy alone, potentially enhancing Amplia’s position in cancer treatment and offering promising implications for stakeholders.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also significant in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 6,104,689
Technical Sentiment Signal: Buy
Current Market Cap: A$136M
For an in-depth examination of ATX stock, go to TipRanks’ Overview page.